A clinical trial involving exenatide-related imaging agents began recruiting as of September 9, 2026. The study, registered as NCT07808879, is titled "Comparison of [68Ga]Ga-HBED-CC-PEG6-Exendin-4 and [68Ga]Ga-HBED-CC-Exendin-4 PET/CT for Insulinoma Localization."
The trial does not have an assigned phase, listed as not applicable. Its current status is recruiting, meaning participant enrollment is underway.
According to the registration, the study compares two exendin-4 based PET/CT imaging tracers. Exendin-4 is the compound on which exenatide, an approved therapy, is based. The listed purpose relates to localization of insulinoma, a type of tumor.
No outcome data, efficacy findings, or safety conclusions have been reported for this trial at this time. The listing reflects only the trial's design and current recruiting status as of the date provided.
Further updates may be posted to the registry as the trial progresses through recruitment and data collection. Readers can consult the compound overview for additional background on exenatide.